Cargando…
Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-co...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986630/ https://www.ncbi.nlm.nih.gov/pubmed/35250004 http://dx.doi.org/10.1097/CJI.0000000000000415 |
_version_ | 1784682571758567424 |
---|---|
author | Zhao, Lijun Li, Yang Jiang, Ning Song, Xue Xu, Jianhua Zhu, Xiangzhi Chen, Cheng Kong, Cheng Wang, Xiaohua Zong, Dan Li, Luan Han, Cen Yin, Li He, Xia |
author_facet | Zhao, Lijun Li, Yang Jiang, Ning Song, Xue Xu, Jianhua Zhu, Xiangzhi Chen, Cheng Kong, Cheng Wang, Xiaohua Zong, Dan Li, Luan Han, Cen Yin, Li He, Xia |
author_sort | Zhao, Lijun |
collection | PubMed |
description | Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-control study. After screening a total of 832 PD-1 inhibitor-treated patients, we identified 42 ir-SAE cases. According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, ir-SAEs were defined as grade ≥3 toxic effects associated with immunotherapy. A total of 126 controls were matched. The crude and adjusted risks of ir-SAEs were estimated by odds ratio (ORs) and 95% CIs using multivariate logistic regression models. Baseline neutrophil-to-lymphocyte ratio (NLR) [per SD increment-adjusted (aOR): 1.16], lactate dehydrogenase (LDH) ≥245 U/L (aOR: 2.39), and antibiotic exposure (aOR: 4.39) were associated with a higher risk of ir-SAEs. When NLR was categorized in 3 groups, significantly higher risks of ir-SAEs (aOR: 4.95) were found in participants in group 3 (>6) than in those in group 1 (<3). Furthermore, NLR (per SD increment-adjusted hazard ratio:1.08) were also significantly associated with shorter overall survival (OS). Baseline LDH ≥245 U/L and antibiotic exposure were no significant association with OS. In conclusion, ir-SAEs were associated between baseline NLR, LDH ≥245 U/L and antibiotic exposure. Lower NLR was correlated with longer OS for cancer. |
format | Online Article Text |
id | pubmed-8986630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-89866302022-04-13 Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors Zhao, Lijun Li, Yang Jiang, Ning Song, Xue Xu, Jianhua Zhu, Xiangzhi Chen, Cheng Kong, Cheng Wang, Xiaohua Zong, Dan Li, Luan Han, Cen Yin, Li He, Xia J Immunother Clinical Studies Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-control study. After screening a total of 832 PD-1 inhibitor-treated patients, we identified 42 ir-SAE cases. According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, ir-SAEs were defined as grade ≥3 toxic effects associated with immunotherapy. A total of 126 controls were matched. The crude and adjusted risks of ir-SAEs were estimated by odds ratio (ORs) and 95% CIs using multivariate logistic regression models. Baseline neutrophil-to-lymphocyte ratio (NLR) [per SD increment-adjusted (aOR): 1.16], lactate dehydrogenase (LDH) ≥245 U/L (aOR: 2.39), and antibiotic exposure (aOR: 4.39) were associated with a higher risk of ir-SAEs. When NLR was categorized in 3 groups, significantly higher risks of ir-SAEs (aOR: 4.95) were found in participants in group 3 (>6) than in those in group 1 (<3). Furthermore, NLR (per SD increment-adjusted hazard ratio:1.08) were also significantly associated with shorter overall survival (OS). Baseline LDH ≥245 U/L and antibiotic exposure were no significant association with OS. In conclusion, ir-SAEs were associated between baseline NLR, LDH ≥245 U/L and antibiotic exposure. Lower NLR was correlated with longer OS for cancer. Lippincott Williams & Wilkins 2022-05 2022-03-07 /pmc/articles/PMC8986630/ /pubmed/35250004 http://dx.doi.org/10.1097/CJI.0000000000000415 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Clinical Studies Zhao, Lijun Li, Yang Jiang, Ning Song, Xue Xu, Jianhua Zhu, Xiangzhi Chen, Cheng Kong, Cheng Wang, Xiaohua Zong, Dan Li, Luan Han, Cen Yin, Li He, Xia Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors |
title | Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors |
title_full | Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors |
title_fullStr | Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors |
title_full_unstemmed | Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors |
title_short | Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors |
title_sort | association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving pd-1 inhibitors |
topic | Clinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986630/ https://www.ncbi.nlm.nih.gov/pubmed/35250004 http://dx.doi.org/10.1097/CJI.0000000000000415 |
work_keys_str_mv | AT zhaolijun associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT liyang associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT jiangning associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT songxue associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT xujianhua associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT zhuxiangzhi associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT chencheng associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT kongcheng associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT wangxiaohua associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT zongdan associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT liluan associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT hancen associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT yinli associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors AT hexia associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors |